In Phase A, participants will acquire distinct doses and schedules of oral ABBV-744 pill to identify Secure dosing routine. Supplemental individuals are going to be enrolled in the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 are going to be offered as "incorporate-on" therapy. https://clinicaleffectivenessofab91457.answerblogs.com/32222176/not-known-factual-statements-about-abbv-744-preclinical-studies-and-results